论文部分内容阅读
目的 :观察FK5 0 6应用中出现的高血糖反应并对其处理进行讨论。 方法 :对FK5 0 6为基础的三联用药方案 (FK5 0 6+MMF +Pred)治疗的 2 0例肾移植患者进行血糖监测 ,观察高血糖及移植后糖尿病 (PTDM)的发生情况 ,对其处理措施进行总结 ,并与CsA为主的三联用药 (CsA +MMF +Pred)进行比较。 结果 :FK5 0 6方案对血糖影响较大 ,高血糖及PTDM发生率分别为 3 0 %和 2 0 % ,高血糖病例的血糖值 ( 12 2± 5 8mmol/L)显著高于CsA组。及时正确的处理可使部分PTDM逆转。 结论 :FK5 0 6对糖代谢的影响以及应用中出现的PTDM是较突出的问题 ,须密切监测并及时采取相应措施
OBJECTIVE: To investigate the hyperglycemic response to FK506 and to discuss its treatment. Methods: Blood glucose was monitored in 20 renal transplant recipients treated with FK506-based triple-drug regimen (FK506 + MMF + Pred). The incidence of hyperglycemia and post-transplant diabetes mellitus (PTDM) The measures were summarized and compared with CsA-based triple therapy (CsA + MMF + Pred). Results: The FK506 program had a significant effect on blood glucose, the incidences of hyperglycemia and PTDM were 30% and 20%, respectively. The blood glucose level of hyperglycemia patients was significantly higher than that of CsA group (12 2 ± 5 8mmol / L). Timely and correct treatment can make part of the PTDM reversed. Conclusion: The impact of FK506 on glucose metabolism and the application of PTDM are more prominent issues, and should be closely monitored and promptly taken corresponding measures